These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 17965123

  • 21. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.
    Kaine JL, Kivitz AJ, Birbara C, Luo AY.
    J Rheumatol; 2007 Feb; 34(2):272-9. PubMed ID: 17304653
    [Abstract] [Full Text] [Related]

  • 22. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 23. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.
    van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M.
    Arthritis Rheum; 2010 Jan; 62(1):75-81. PubMed ID: 20039396
    [Abstract] [Full Text] [Related]

  • 24. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease.
    Hagihara Y, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, Kamata N, Sogawa M, Shiba M, Tanigawa T, Tominaga K, Watanabe T, Fujiwara Y, Hirota Y, Arakawa T.
    J Crohns Colitis; 2014 Mar; 8(3):223-33. PubMed ID: 24011513
    [Abstract] [Full Text] [Related]

  • 25. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 26. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 27. Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.
    Maruszak H, Jeganathan S, Smith DE, Robertson P, Barnes T, Furner V.
    HIV Med; 2012 Jul; 13(6):352-7. PubMed ID: 22296264
    [Abstract] [Full Text] [Related]

  • 28. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
    Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P.
    Rheumatology (Oxford); 2006 Jan; 45(1):106-11. PubMed ID: 16287919
    [Abstract] [Full Text] [Related]

  • 29. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT, Changolkar AK, Scott McKenzie R.
    J Med Econ; 2012 Jan; 15(2):332-9. PubMed ID: 22168788
    [Abstract] [Full Text] [Related]

  • 30. Immune response to influenza vaccination in community-dwelling Chinese elderly persons.
    Hui SL, Chu LW, Peiris JS, Chan KH, Chu D, Tsui W.
    Vaccine; 2006 Jun 19; 24(25):5371-80. PubMed ID: 16713661
    [Abstract] [Full Text] [Related]

  • 31. Immunogenicity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis.
    Polachek A, Korobko U, Mader-Balakirski N, Arad U, Levartovsky D, Kaufman I, Anouk M, Litinsky I, Wigler I, Mendelson E, Paran D, Matz H, Caspi D, Mandelboim M, Elkayam O.
    Clin Exp Rheumatol; 2015 Jun 19; 33(2):181-6. PubMed ID: 25738420
    [Abstract] [Full Text] [Related]

  • 32. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.
    Arthritis Rheum; 2009 Nov 19; 60(11):3180-9. PubMed ID: 19877027
    [Abstract] [Full Text] [Related]

  • 33. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis.
    Toonen EJ, Coenen MJ, Kievit W, Fransen J, Eijsbouts AM, Scheffer H, Radstake TR, Creemers MC, de Rooij DJ, van Riel PL, Franke B, Barrera P.
    Ann Rheum Dis; 2008 Aug 19; 67(8):1174-7. PubMed ID: 18385279
    [Abstract] [Full Text] [Related]

  • 34. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
    Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y.
    J Rheumatol; 2011 Nov 19; 38(11):2346-54. PubMed ID: 21965648
    [Abstract] [Full Text] [Related]

  • 35. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF.
    Scand J Rheumatol; 2005 Nov 19; 34(5):353-8. PubMed ID: 16234182
    [Abstract] [Full Text] [Related]

  • 36. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.
    Ann Rheum Dis; 2011 Oct 19; 70(10):1719-25. PubMed ID: 21719446
    [Abstract] [Full Text] [Related]

  • 37. Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial.
    Matsumoto H, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, Kamata N, Sogawa M, Shiba M, Tanigawa T, Tominaga K, Watanabe T, Fujiwara Y, Hirota Y, Arakawa T.
    J Gastroenterol; 2015 Aug 19; 50(8):876-86. PubMed ID: 25672513
    [Abstract] [Full Text] [Related]

  • 38. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD.
    Ann Rheum Dis; 2008 May 19; 67(5):710-2. PubMed ID: 18079191
    [Abstract] [Full Text] [Related]

  • 39. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
    Arthritis Rheum; 2007 May 19; 56(5):1417-23. PubMed ID: 17469098
    [Abstract] [Full Text] [Related]

  • 40. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice.
    Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, França IL, Carvalho JF, Sampaio-Barros PD, Goncalves CR, Borba EF, Timenetsky Mdo C, Precioso AR, Duarte A, Bonfa E, Laurindo IM.
    Ann Rheum Dis; 2011 Dec 19; 70(12):2144-7. PubMed ID: 21859696
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.